Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study

D D Orsted; B G Nordestgaard; S E Bojesen

doi:10.1093/annonc/mdt590

Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study

D D Orsted, B G Nordestgaard, S E Bojesen

Department of Clinical Medicine

22 Citations (Scopus)

Abstract

BACKGROUND: Testosterone is an important anabolic hormone in humans and in vitro testosterone stimulates growth of lung and colon cancer cells. We tested the hypothesis that plasma testosterone associate with increased risk of cancer and with increased risk of early death after cancer.

MATERIALS AND METHODS: Plasma testosterone was measured in 8771 20- to 94-year-old men and women who participated in a prospective study of the general population. Participants were included in 1981-1983 and followed for a median of 22 years (range: 0-30 years).

RESULTS: During follow-up, 1140 men and 809 women developed cancer. For risk of early death after cancer, for men, after adjustment for age at diagnosis, tumour stage at diagnosis, and time since blood-sampling, the hazard ratio was 1.30 [95% confidence interval (CI) 1.03-1.65] for the 2nd quintile, 1.31 (1.02-1.67) for the 3rd quintile, 1.52 (1.19-1.93) for the 4th quintile, and 1.52 (1.20-1.91) for the 5th quintile, versus the 1st quintile. For women, corresponding hazard ratios were 1.09 (0.81-1.46), 1.17 (0.86-1.59), 1.03 (0.76-1.39), and 1.80 (1.32-2.46). For risk of cancer, multifactorially adjusted hazard ratios for risk of any cancer were 1.07 (95% CI 0.98-1.18) and 1.06 (0.93-1.22) for men and women, respectively, when testosterone doubled. For both men and women, a doubling of testosterone was not associated with risk of any cancer type.

CONCLUSIONS: In this prospective study of 8771 men and women from the general population followed for >30 years, increased levels of testosterone were associated with a 30%-80% increased risk of early death after cancer, but unchanged risk of incident cancer.

Original language	English
Journal	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume	25
Issue number	3
Pages (from-to)	712-718
Number of pages	7
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdt590
Publication status	Published - Mar 2014

Keywords

Adult
Aged
Aged, 80 and over
Cohort Studies
Female
Humans
Male
Middle Aged
Neoplasms
Prognosis
Prospective Studies
Risk
Risk Factors
Testosterone
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdt590

Cite this

Plasma testosterone in the general population, cancer prognosis and cancer risk : a prospective cohort study. / Orsted, D D; Nordestgaard, B G ; Bojesen, S E.

In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Vol. 25, No. 3, 03.2014, p. 712-718.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{757f6d827d9846dc8ef2326fa0628537,

title = "Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study",

abstract = "BACKGROUND: Testosterone is an important anabolic hormone in humans and in vitro testosterone stimulates growth of lung and colon cancer cells. We tested the hypothesis that plasma testosterone associate with increased risk of cancer and with increased risk of early death after cancer.MATERIALS AND METHODS: Plasma testosterone was measured in 8771 20- to 94-year-old men and women who participated in a prospective study of the general population. Participants were included in 1981-1983 and followed for a median of 22 years (range: 0-30 years).RESULTS: During follow-up, 1140 men and 809 women developed cancer. For risk of early death after cancer, for men, after adjustment for age at diagnosis, tumour stage at diagnosis, and time since blood-sampling, the hazard ratio was 1.30 [95% confidence interval (CI) 1.03-1.65] for the 2nd quintile, 1.31 (1.02-1.67) for the 3rd quintile, 1.52 (1.19-1.93) for the 4th quintile, and 1.52 (1.20-1.91) for the 5th quintile, versus the 1st quintile. For women, corresponding hazard ratios were 1.09 (0.81-1.46), 1.17 (0.86-1.59), 1.03 (0.76-1.39), and 1.80 (1.32-2.46). For risk of cancer, multifactorially adjusted hazard ratios for risk of any cancer were 1.07 (95% CI 0.98-1.18) and 1.06 (0.93-1.22) for men and women, respectively, when testosterone doubled. For both men and women, a doubling of testosterone was not associated with risk of any cancer type.CONCLUSIONS: In this prospective study of 8771 men and women from the general population followed for >30 years, increased levels of testosterone were associated with a 30%-80% increased risk of early death after cancer, but unchanged risk of incident cancer.",

keywords = "Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Humans, Male, Middle Aged, Neoplasms, Prognosis, Prospective Studies, Risk, Risk Factors, Testosterone, Young Adult",

author = "Orsted, {D D} and Nordestgaard, {B G} and Bojesen, {S E}",

year = "2014",

month = mar,

doi = "10.1093/annonc/mdt590",

language = "English",

volume = "25",

pages = "712--718",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Plasma testosterone in the general population, cancer prognosis and cancer risk

T2 - a prospective cohort study

AU - Orsted, D D

AU - Nordestgaard, B G

AU - Bojesen, S E

PY - 2014/3

Y1 - 2014/3

N2 - BACKGROUND: Testosterone is an important anabolic hormone in humans and in vitro testosterone stimulates growth of lung and colon cancer cells. We tested the hypothesis that plasma testosterone associate with increased risk of cancer and with increased risk of early death after cancer.MATERIALS AND METHODS: Plasma testosterone was measured in 8771 20- to 94-year-old men and women who participated in a prospective study of the general population. Participants were included in 1981-1983 and followed for a median of 22 years (range: 0-30 years).RESULTS: During follow-up, 1140 men and 809 women developed cancer. For risk of early death after cancer, for men, after adjustment for age at diagnosis, tumour stage at diagnosis, and time since blood-sampling, the hazard ratio was 1.30 [95% confidence interval (CI) 1.03-1.65] for the 2nd quintile, 1.31 (1.02-1.67) for the 3rd quintile, 1.52 (1.19-1.93) for the 4th quintile, and 1.52 (1.20-1.91) for the 5th quintile, versus the 1st quintile. For women, corresponding hazard ratios were 1.09 (0.81-1.46), 1.17 (0.86-1.59), 1.03 (0.76-1.39), and 1.80 (1.32-2.46). For risk of cancer, multifactorially adjusted hazard ratios for risk of any cancer were 1.07 (95% CI 0.98-1.18) and 1.06 (0.93-1.22) for men and women, respectively, when testosterone doubled. For both men and women, a doubling of testosterone was not associated with risk of any cancer type.CONCLUSIONS: In this prospective study of 8771 men and women from the general population followed for >30 years, increased levels of testosterone were associated with a 30%-80% increased risk of early death after cancer, but unchanged risk of incident cancer.

AB - BACKGROUND: Testosterone is an important anabolic hormone in humans and in vitro testosterone stimulates growth of lung and colon cancer cells. We tested the hypothesis that plasma testosterone associate with increased risk of cancer and with increased risk of early death after cancer.MATERIALS AND METHODS: Plasma testosterone was measured in 8771 20- to 94-year-old men and women who participated in a prospective study of the general population. Participants were included in 1981-1983 and followed for a median of 22 years (range: 0-30 years).RESULTS: During follow-up, 1140 men and 809 women developed cancer. For risk of early death after cancer, for men, after adjustment for age at diagnosis, tumour stage at diagnosis, and time since blood-sampling, the hazard ratio was 1.30 [95% confidence interval (CI) 1.03-1.65] for the 2nd quintile, 1.31 (1.02-1.67) for the 3rd quintile, 1.52 (1.19-1.93) for the 4th quintile, and 1.52 (1.20-1.91) for the 5th quintile, versus the 1st quintile. For women, corresponding hazard ratios were 1.09 (0.81-1.46), 1.17 (0.86-1.59), 1.03 (0.76-1.39), and 1.80 (1.32-2.46). For risk of cancer, multifactorially adjusted hazard ratios for risk of any cancer were 1.07 (95% CI 0.98-1.18) and 1.06 (0.93-1.22) for men and women, respectively, when testosterone doubled. For both men and women, a doubling of testosterone was not associated with risk of any cancer type.CONCLUSIONS: In this prospective study of 8771 men and women from the general population followed for >30 years, increased levels of testosterone were associated with a 30%-80% increased risk of early death after cancer, but unchanged risk of incident cancer.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Cohort Studies

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasms

KW - Prognosis

KW - Prospective Studies

KW - Risk

KW - Risk Factors

KW - Testosterone

KW - Young Adult

U2 - 10.1093/annonc/mdt590

DO - 10.1093/annonc/mdt590

M3 - Journal article

C2 - 24567517

SN - 0923-7534

VL - 25

SP - 712

EP - 718

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -

Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this